title: Iron release in erythrocytes from patients with beta-thalassemia.
abstract: Our previous studies have shown that iron is released in a free (desferrioxamine-chelatable) form when erythrocytes undergo oxidative stress (incubation with oxidizing agents or aerobic incubation in buffer for 24-60 h (a model of rapid in vitro ageing)). The release is accompanied by oxidative alterations of membrane proteins as well as by the appearance of senescent antigen, a signal for termination of old erythrocytes. In hemolytic anemias by hereditary hemoglobin alterations an accelerated removal of erythrocytes occurs. An increased susceptibility to oxidative damage has been reported in beta-thalassemic erythrocytes. Therefore we have investigated whether an increased iron level and an increased susceptibility to iron release could be observed in the erythrocytes from patients with beta-thalassemia. Erythrocytes from subjects with thalassemia intermedia showed an extremely higher content (0 time value) of free iron and methemoglobin as compared to controls. An increase, although non-statistically-significant, was seen in erythrocytes from subjects with thalassemia major. Upon aerobic incubation for 24 h the release of iron in beta-thalassemic erythrocytes was by far greater than in controls, with the exception of thalassemia minor. When the individual values for free iron content (0 time) seen in thalassemia major and intermedia were plotted against the corresponding values for HbF, a positive correlation (P < 0.001) was observed. Also, a positive correlation (P < 0.01) was seen between the values for free iron release (24 h incubation) and the values for HbF. These results suggest that the presence of HbF is a condition favourable to iron release. Since in beta-thalassemia the persistance of HbF is related to the lack or deficiency of beta chains and therefore to the excess of alpha chains, the observed correlation between free iron and HbF, is consistent with the hypothesis by others that excess of alpha chains represents a prooxidant factor.
authors.affiliation: Istituto di Patologia Generale, Università di Siena, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Ciccoli
authors.forename: C
authors.initials: C
authors.lastname: Signorini
authors.forename: C
authors.initials: C
authors.lastname: Scarano
authors.forename: V
authors.initials: V
authors.lastname: Rossi
authors.forename: S
authors.initials: S
authors.lastname: Bambagioni
authors.forename: M
authors.initials: M
authors.lastname: Ferrali
authors.forename: M
authors.initials: M
authors.lastname: Comporti
mesh_terms: D000328:Adult; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D005319:Fetal Hemoglobin / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism*; D009002:Monomethylhydrazine / Q000494:pharmacology; D010659:Phenylhydrazines / Q000494:pharmacology; D012016:Reference Values; D017086:beta-Thalassemia / Q000378:metabolism*
chemical_list: D010659:Phenylhydrazines; C030299:phenylhydrazine; D005319:Fetal Hemoglobin; D007501:Iron; D005978:Glutathione; D009002:Monomethylhydrazine